Pemoline Stats & Data

Pemoline is a CNS stimulant formerly used for ADHD and narcolepsy; FDA approval was withdrawn in 2005 after reports of acute liver failure and death, despite earlier monitoring recommendations. Avoid alcohol entirely while on pemoline; DrugBank explicitly lists alcohol avoidance and caffeine limitation, and alcohol adds independent liver risk. Baseline and periodic liver function testing is prudent if any exposure occurs; watch for warning signs of DILI (e.g., right‑upper‑quadrant pain, dark urine, pruritus, jaundice, prolonged nausea/fatigue) and stop immediately if they appear. Do not re‑challenge after suspected pemoline‑related liver injury due to risk of recurrence with greater severity. Roughly half of an oral dose is renally excreted unchanged and the serum half‑life is near 12 hours, so redosing stacks substantially; spacing doses and avoiding late‑day dosing reduces insomnia and overstimulation. Given limited euphoric effects relative to amphetamines, users may be tempted to escalate doses; this increases adverse effect risk without reliably improving therapeutic benefit. Combining with MAOIs or other stimulants increases cardiovascular/central adverse events and is discouraged by interaction guides; if any combination is unavoidable in clinical contexts, specialist oversight is essential. Because pemoline is or has been controlled (e.g., CSA Schedule IV historically) and withdrawn in many markets, products circulating online may be mislabelled; reagent testing will not assess hepatotoxicity, so sourcing does not mitigate this core risk. Consider alternative, better‑characterized treatments where available; if used off‑label, employ the lowest effective dose for the shortest feasible duration and schedule rest days.